Related references
Note: Only part of the references are listed.Prospective analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, UK
Modar Khalil et al.
JOURNAL OF HEADACHE AND PAIN (2014)
ICHD-3 beta is published. Use it immediately
Jes Olesen
CEPHALALGIA (2013)
OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline
Stephen D. Silberstein et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2013)
Disability, HRQoL and resource use among chronic and episodic migraineurs: Results from the International Burden of Migraine Study (IBMS)
A. M. Blumenfeld et al.
CEPHALALGIA (2011)
OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Analyses of the 56-Week PREEMPT Clinical Program
Sheena K. Aurora et al.
HEADACHE (2011)
Chronic migraine plus medication overuse headache: two entities or not?
Andrea Negro et al.
JOURNAL OF HEADACHE AND PAIN (2011)
Botulinum toxin type-A in the prophylactic treatment of medication-overuse headache: a multicenter, double-blind, randomized, placebo-controlled, parallel group study
Giorgio Sandrini et al.
JOURNAL OF HEADACHE AND PAIN (2011)
Global prevalence of chronic migraine: A systematic review
J. L. Natoli et al.
CEPHALALGIA (2010)
Sensitisation of spinal cord pain processing in medication overuse headache involves supraspinal pain control
A. Perrotta et al.
CEPHALALGIA (2010)
Migraine prevalence by age and sex in the United States: A life-span study
T. W. Victor et al.
CEPHALALGIA (2010)
OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial
S. K. Aurora et al.
CEPHALALGIA (2010)
OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial
H. C. Diener et al.
CEPHALALGIA (2010)
Method of Injection of OnabotulinumtoxinA for Chronic Migraine: A Safe, Well-Tolerated, and Effective Treatment Paradigm Based on the PREEMPT Clinical Program
Andrew Blumenfeld et al.
HEADACHE (2010)
OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double-Blind, Randomized, Placebo-Controlled Phases of the PREEMPT Clinical Program
David W. Dodick et al.
HEADACHE (2010)
Management of medication overuse headache: 1-year randomized multicentre open-label trial
K. Hagen et al.
CEPHALALGIA (2009)
Economic Burden of Transformed Migraine: Results From the American Migraine Prevalence and Prevention (AMPP) Study
Julie Munakata et al.
HEADACHE (2009)
Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults
S. Silberstein et al.
CEPHALALGIA (2008)
The importance of placebo in headache research
H-C Diener et al.
CEPHALALGIA (2008)
Chronic migraine in the population - Burden, diagnosis, and satisfaction with treatment
Marcelo E. Bigal et al.
NEUROLOGY (2008)
Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study
H-C Diener et al.
CEPHALALGIA (2007)
Evidence-based understanding of medication-overuse headache: Clinical implications
David Dodick et al.
HEADACHE (2006)
Discontinuation of medication overuse in headache patients: recovery of therapeutic responsiveness
P. Zeeberg et al.
CEPHALALGIA (2006)
Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A
KR Aoki
NEUROTOXICOLOGY (2005)
Medication overuse headache: rates and predictors for relapse in a 4-year prospective study
Z Katsarava et al.
CEPHALALGIA (2005)
Medication-overuse headache: a worldwide problem
HC Diener et al.
LANCET NEUROLOGY (2004)
Transformed migraine and medication overuse in a tertiary headache centre - clinical characteristics and treatment outcomes
ME Bigal et al.
CEPHALALGIA (2004)
Prevalence and burden of migraine in the United States: Data from the American Migraine Study II
RB Lipton et al.
HEADACHE (2001)
Share Paper
